B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Background The management of patients with chronic lymphocytic leukaemia is currently
undergoing improvements due to novel therapies and a plethora of biological and genetic …

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine,
cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with …

Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral
heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome …

Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary
course of cancer. Chronic lymphocytic leukaemia (CLL) is a highly informative model for …

Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment
of relapsed/refractory chronic lymphocytic leukemia (CLL). To evaluate idelalisib as front …

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes,
involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes …

Purpose To determine the clinical significance of flow cytometric minimal residual disease
(MRD) quantification in chronic lymphocytic leukemia (CLL) in addition to pretherapeutic risk …

In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have
been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited …